Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
IGC Pharma (NYSE American: IGC) reported Q2 FY2026 results for the quarter ended September 30, 2025, and outlined operational progress.
Key items: Phase 2 CALMA enrollment surpassed 50%; a strategic divestiture of a Vancouver manufacturing facility closed for $2.7 million producing an approximate $1.1 million non-cash profit and eliminating $600,000 in annual expenses; other net income rose 2,407%; R&D spending increased 73% to $1.6 million; revenue declined ~54% to $191,000; net loss was $1.8 million ($0.02/share). The company noted NIA recognition for its AI work and ongoing pipeline advances including IGC-M3 and patent allowance for IGC510.
IGC Pharma (NYSE:IGC) announced that the USPTO granted U.S. Patent No. 12,465,589 on November 11, 2025 for "Methods and Composition for Treating CNS Disorders."
The patent covers the proprietary formulation used in IGC-AD1, the company's lead candidate now in the Phase 2 CALMA trial for agitation in Alzheimer's disease, and claims effects on amyloid-beta, tau phosphorylation, mitochondrial function, and behavioral symptoms including agitation, memory, cognition, anxiety, and sleep disturbances.
IGC Pharma (NYSE American: IGC) will host a mid-year fiscal 2026 shareholder update call on Monday, November 17, 2025 at 11:00 a.m. ET to review operational progress for the quarter and mid-year ended September 30, 2025.
Participants may join by phone using access code 146922 or via live webcast at the provided URL; a replay will be available until February 12, 2026.
IGC Pharma (NYSE:IGC) announced an expansion of its AI-powered in-silico drug discovery platform on November 3, 2025, adding retrosynthetic analysis, molecular docking, toxicology/genotoxic assessment, and predictive bioactivity modeling.
The upgrade aims to accelerate identification and optimization of Alzheimer's candidates by prioritizing compounds in its patent portfolio, predicting target interactions, and flagging toxicity earlier to reduce experimental burden. Ongoing programs noted include IGC-AD1 (Phase 2), TGR-63 (preclinical plaque clearance in cortex and hippocampus), IGC-1C (tau/GLP-1 dual action), and IGC-1A (AI-identified GLP-1 agonist).
IGC Pharma (NYSE American: IGC) announced that its project "AHA: Agentic Harmonization Assistant" was selected as a semi-finalist in the $1 million Alzheimer's Insights AI Prize organized by the Alzheimer's Disease Data Initiative. The company said AHA builds on its MINT-AD deep-learning platform, which integrates clinical, neuroimaging, genetic, lifestyle, cognitive, and genomic data to address data harmonization in Alzheimer’s drug discovery.
The semi-final presentation is scheduled for December 5, 2025 in San Diego, following the CTAD conference. IGC framed the selection as recognition of its AI-driven research capabilities and team execution.
IGC Pharma (NYSE American:IGC) announced expansion of its Phase 2 CALMA trial of investigational IGC-AD1 for agitation in Alzheimer's disease with a new clinical site at the University of South Florida Department of Psychiatry and Behavioral Neurosciences effective October 14, 2025.
Enrollment at the USF site has begun with four participants already enrolled. CALMA is a randomized, double-blind, placebo-controlled Phase 2 study evaluating the efficacy and safety of IGC-AD1; the company says the USF site will help accelerate recruitment and diversify participants as the trial continues to expand across North America.
IGC Pharma (NYSE American: IGC) held its Annual Meeting on October 10, 2025 where stockholders approved all proposals disclosed in the Definitive Proxy on Schedule 14A dated August 18, 2025.
Approved actions include: (i) election of Ram Mukunda and James Moran as Class C directors through the 2028 annual meeting; (ii) ratification of Manohar Chowdhry & Associates as independent registered public accounting firm for fiscal 2026; (iii) authorization to grant 5,000,000 shares of common stock to employees, advisors, directors, and consultants under board/CEO-set metrics; and (iv) amendment to increase authorized common shares from 150,000,000 to 600,000,000.
IGC (NYSE American: IGC) announced preclinical in-vitro data for IGC-1C on October 7, 2025, describing a novel approach that targets tau protein liquid-liquid phase separation (LLPS).
Key findings include inhibition and dissolution of zinc-mediated tau condensates, reduction in condensate size and number, prevention of conversion to amyloid fibrils, and a measured tau binding affinity of Kd 3.95 ± 0.32 μM. IGC-1C was permeable and well tolerated in SH-SY5Y cell cultures. The company plans additional animal validation studies with the stated goal of advancing IGC-1C toward clinical trials.
IGC Pharma (NYSE American: IGC) announced the addition of Ichor Research in Syracuse, New York, as a new clinical trial site for its ongoing Phase 2 CALMA trial. The study evaluates IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease patients.
The trial, designed as a randomized, double-blind, placebo-controlled study, will be led by Principal Investigator Dr. Karl F. Hafner, M.D. at the new site. The CALMA trial aims to assess the safety and efficacy of IGC-AD1 in reducing agitation symptoms, which are among the most common and distressing behavioral symptoms in Alzheimer's patients.
IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its Alzheimer's disease candidate TGR-63. The research reveals TGR-63's dual mechanism of action, demonstrating its ability to target both beta-amyloid (Aβ) plaques and tau protein aggregation, two major hallmarks of Alzheimer's disease.
The studies showed that TGR-63 suppresses tau fibril formation at micromolar concentrations and maintains structural stability under physiological conditions. MALDI mass spectrometry detected the compound in serum samples at both 1- and 24-hours post-administration, indicating strong pharmacological resilience and systemic delivery potential.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
